Olema Oncology
Olema Oncology is dedicated to developing targeted therapies for women's cancers, with a focus on palazestrant (OP-1250) for ER+/HER2- metastatic breast cancer.
Company Overview
Olema Oncology is dedicated to the discovery, development, and commercialization of targeted therapies for women's cancers. The company is strategically located in San Francisco, CA, and Cambridge, MA. Olema Oncology focuses on creating better treatment protocols for women living with cancer and is committed to improving outcomes for patients with metastatic breast cancer.
Palazestrant (OP-1250) Development
Olema Oncology is developing palazestrant (OP-1250), an orally bioavailable Complete Estrogen Receptor Antagonist (CERAN) and selective ER degrader (SERD). This investigational agent is intended for the treatment of ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer. OP-1250 is being evaluated both as monotherapy and in combination with other treatments.
Clinical Trials of Palazestrant (OP-1250)
Olema Oncology has completed enrollment in Phase 1b/2 clinical studies of palazestrant (OP-1250) in combination with ribociclib and palbociclib. Results showed that the combination with ribociclib was well tolerated with no new safety signals or increased toxicity. An 85% clinical benefit rate was observed across all eligible patients treated with palazestrant and ribociclib.
Pipeline and Future Development
In addition to OP-1250, Olema Oncology is developing OP-3136, a KAT6 inhibitor targeting ER+/HER2+ metastatic breast cancer and castrate-resistant prostate cancer. The company's pipeline reflects its commitment to advancing therapies for difficult-to-treat cancers and partnering with patients to bring effective treatments to market.
Corporate Culture and Employee Benefits
Olema Oncology fosters a culture of collaboration, understanding, and inclusion. The company offers a flexible work environment, competitive compensation, and equal employment opportunities. Olema is dedicated to ensuring that its employees thrive in the best of both coasts, providing robust support for personal and professional growth.